ZURCHER KANTONALBANK FINANCE (GUERNSEY) LIMITED

Zurcher Kantonalbank Finance (Guernsey) Limited Stock

Z09A5Z

CH1329114883

Real-time Bid/Ask 06:58:52 2024-06-03 EDT
96.52 ^USD / 97.02 ^USD	+1.18%

1 month

-0.47%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart Zurcher Kantonalbank Finance (Guernsey) Limited

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02	RE
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	06-01	BU
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	06-01	CI

More news

Quotes 5-day view

Date	Price	Change
24-05-31	95.64	+0.51%
24-05-30	95.15	+0.21%
24-05-29	94.95	-1.22%
24-05-28	96.12	-1.19%
24-05-24	97.28	-0.96%

Delayed Quote Swiss Exchange

Last update May 31, 2024 at 11:20 am

More quotes

Static data

Product type	Obligations Convertibles
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	ZKB
	Z09A5Z
ISIN	CH1329114883
Date issued	2024-03-21
Strike	51.59 $
Maturity	2025-03-21 (292 Days)
Parity	0.05 : 1
Emission price	100 $
Emission volume	N/A
Settlement	les deux
Currency	USD

Technical Indicators

Highest since issue	101.1 $
Lowest since issue	94.95 $
Spread	5 $
Spread %	0.52%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus